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Abstract
Background—While dezocine is a partial mu opioid receptor agonist, it is not a controlled 
substance. Thus, the characterization of the molecular targets of dezocine is critical for scientific 
and clinical implications. The goal of this study is to characterize molecular targets for dezocine 
and their implications.
Methods—A binding screen for dezocine was performed on 44 available receptors and 
transporter proteins. Functional assays for the novel targets were performed along with 
computation calculations to locate the binding site. A G protein activation study was performed 
for the human kappa opioid receptor to determine whether dezocine is a kappa antagonist. Data 
are presented as mean ± SE.
Results—The affinities for dezocine were 3.7±0.7 nM for the mu receptor, 527±70 nM for the 
delta receptor, and 31.9±1.9 nM for the kappa receptor. Dezocine failed to induce G protein 
activation with kappa opioid receptor and concentration dependently inhibited kappa agonist 
(salvinorin A and nalbuphine) induced receptor activation, indicating that dezocine is a kappa 
antagonist. Two novel molecular targets (norepinephrine transporter, NET; and serotonin 
transporter, SERT) were identified. Dezocine concentration-dependently inhibited norepinephrine 
and serotonin reuptake in vitro. The half maximal inhibitory concentrations (expressed as pIC50) 
were 5.68±0.11 for NET and 5.86 ± 0.17 for SERT. Dezocine occupied the binding site for known 
NET and SERT inhibitors.
Conclusions—The unique molecular pharmacological profile of dezocine as a partial mu 
receptor agonist, a kappa receptor antagonist and a norepinephrine and serotonin reuptake 
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inhibitor (via NET and SERT) was revealed. These discoveries reveal potentially important novel 
clinical implications and drug interactions of dezocine.
Introduction
Dezocine is an opioid medication that is structurally similar to pentazocine, a mixed opioid 
receptor partial agonist/antagonist developed in 1970’s by the American Home Products 
Corporation.(1) Dezocine was approved by the Food and Drug Administration for 
perioperative care management but was discontinued with the closure of its parent company. 
PubMed lists only 74 papers related to dezocine*, with the first paper published in 1978 in 
Anesthesia & Analgesia demonstrating its use for postoperative pain management.(1) 
Although no longer used clinically in Western countries, dezocine is gaining popularity in 
China as an alternative medication for perioperative pain management.(2)
Dezocine is an opioid mu receptor partial agonist/antagonist. (1) Because of its partial mu 
agonism, it exhibits a “ceiling effect” for respiratory depression (a notorious and fatal side 
effect caused by commonly used clinical opiates). Though initially identified as a kappa 
receptor agonist, a later study suggests that dezocine is a kappa receptor antagonist. (3) 
Further study is needed to resolve this discrepancy. Since dezocine is a partial mu 
antagonist, in theory, a concerted use of dezocine together with a mu receptor agonist like 
morphine should decrease the analgesia effect of morphine significantly. However, it is 
reported that the combination of morphine and dezocine increases the analgesic effects 
significantly,(4) indicating that dezocine may induce analgesia through an additional 
mechanism(s).
Opiate receptors belong to the G protein coupled receptor (GPCR) family. It is highly 
possible that, in addition to opiate receptors, opioids could interact with other GPCRs. In 
this study, we hypothesized that dezocine might also act at other membrane receptors, and 
we therefore screened a large group of available recombinant GPCRs and transporter 
proteins in an attempt to identify novel pharmacological targets for dezocine. We further 
investigated whether dezocine was a kappa receptor agonist or antagonist. The molecular 
interactions with the target proteins were analyzed using available crystal structures and 
molecular models for docking calculations.
Materials and Methods
All chemicals (except those specified otherwise) were obtained from Sigma-Aldrich (St. 
Louis, MO) and were reagent grade or higher. Dezocine was obtained from Young's River 
pharmaceutical group (Taizhou, Jiangsu, China) with 99.9% purity. All chemicals were used 
without further purification. The chemical structures of the ligands that have the same 
targets as dezocine and were used for comparison purposes in this study are listed in figure 
1.
*www.pubmed.com, last date accessed April 18, 2013
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Radioligand Binding Assays and Affinity Determination
A primary binding screen for dezocine was performed on 44 available receptors (mostly 
GPCRs, see Table 1). Evidence for interaction was based on the inhibition of the reference 
ligandbinding signal. Dezocine was diluted in standard binding buffer (50mM Tris-HCl, 
10mM MgCl2, 0.1mM EDTA, pH 7.4) to a final concentration of 10 µM. Briefly, 50µL 
aliquots of radioactive ligand (5nM) were added to wells of a 96-well plate, which contained 
25µL of the reference or test ligands. We employed transfected cell lines expressing mainly 
human (unless otherwise specified) recombinant receptors, monoamine transporters, or ion 
channels for crude membrane preparation. Detailed information about our membrane 
preparation can be obtained from the protocol online†. Crude membrane fractions containing 
the receptors were resuspended in standard binding buffer and 50µL aliquots added to each 
well. The reactions were incubated at room temperature for 1.5 hours to allow for 
radioligand binding equilibration. Bound radioactivity was harvested by rapid filtration 
through a 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-wel Filtermate 
harvester (PerkinElmer, Waltham, MA). The dried filters were treated with melted 
scintillant and a Microbeta scintillation counter (PerkinElmer) was utilized to measure the 
radioactivity retained on the filter.
The secondary binding assay was performed only when the inhibition in the primary screen 
was over 50%. A secondary binding assay was utilized to determine the binding affinity for 
the identified receptor. Dezocine was prepared in standard binding buffer and serially 
diluted to the desired concentrations.
50µL aliquots of radioactive ligand (5nM) were added to wells of a 96-well plate, which 
contained 25µL aliquots of dezocine. 50µL of a crude membrane fraction of cells expressing 
the respective receptors were applied to each well. Reaction incubation, harvesting and 
radioactivity measurement procedures from the primary assay were repeated. Affinity is 
expressed as pKi (-logKi).
G protein activation by kappa receptor treated with agonists, partial agonists and 
antagonists
Membrane preparations of recombinant human kappa opioid receptor expressed in the 
mammalian cell line Chem-5 were obtained from Millipore (Billerica, MA). The effects of 
specific kappa opioid receptor ligands on the activation of the recombinant receptor were 
investigated by measuring G protein activation in vitro. Nalbuphine and salvinorin A (full 
agonist) and nor-binaltorphimine (antagonist) were utilized as controls.
The assay reports the initial rates of activation of heterotrimeric G proteins (Gαii1β1γ2) on 
an agonist-bound receptor by measuring the accumulation of [35S]-GTPγS (non-
hydrolyzable analog of GTP) bound to the activated Gαi1 subunit. Myristoylated Gαi1 was 
expressed in E. coli and purified as previously described. (5) Recombinant human β1γ2 
subunits of G protein were expressed in baculovirus-infected Sf9 cells and purified as 
previously described. (6) The G protein activation assay was conducted as follows (final 
†http://pdsp.med.unc.edu/PDSP%20Protocols%20II%202013-03-28.pdf, pages 18–24, last date accessed: October 15, 2013
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concentrations in 50µL reaction mixture are given in parentheses): the membrane sample 
was diluted into ice-cold 10 mM 3-(N-morpholino) propanesulfonic acid (MOPS) buffer to 
reach a protein concentration of 40 ng/µL. 10 µL of the diluted dispersion were dispensed 
into pre-siliconized glass tubes and mixed with the ligand in MOPS buffer containing 0.1% 
(w/v) BSA. Upon addition of a mixture of Gαi1 (100 nM) and Gβ1γ2 (500 nM), the tubes 
were incubated on ice for 30 minutes. The reaction was started by addition of MOPS buffer 
pH=7.5 (50 mM), EDTA (1 mM), MgCl2 (3 mM), GDP (4 µM), BSA (0.3% w/v), NaCl 
(100 mM), DTT (1 mM), and [35S]-GTPγS (5 nM, 1250 Ci/mmol) followed by rapid 
transfer of the tubes to a water bath at 30 °C. The incubation continued for 45 minutes. The 
reaction was terminated by addition of 2 mL of ice-cold stop solution, TNMg (20 mM Tris-
HCl pH=8.0, 100 mM NaCl, and 25 mM MgCl2). The reaction mixture was rapidly filtered 
through nitrocellulose filters (Millipore). Filters were washed four times with 2 mL each of 
cold TNMg buffer, dried, placed in scintillation vials filled with ScintiSafe Econo F 
scintillation liquid (Fisher, Waltham, MA), and the radioactivity counted. Duplicate samples 
corresponding to every ligand concentration point were counted.
To test whether dezocine could antagonize the full agonists, the kappa receptor was 
preactivated with either nalbuphine (250 nM) or salvinorin A (20 nM), a highly selective 
non-opioid kappa receptor agonists with strong affinity.(7) The kappa receptor was then 
treated with increasing concentrations of dezocine.
Norepinephrine transporter (NET) and serotonin transporter (SERT) reuptake assay
The potency of dezocine as an inhibitor of norepinephrine and serotonin uptake on human 
cloned NET and SERT, stably expressed in Human Embryonic Kidney 293 cells, was 
determined using the neurotransmitter assay kit from the Molecular Devices (Sunnyvale, 
CA) as described previously.(8) In brief, Human Embryonic Kidney 293 cells were plated in 
Poly-L-Lys (PLL) coated 384-well black clear bottom cell culture plates in DMEM + 1% 
dFBS, at a density of 15,000 cells per well in a total volume of 40 µl. The cells were 
incubated for a minimum of 6 hours before use in the assays. The medium was removed and 
20 µl of assay buffer (20 mM HEPES, 1x HBSS, pH 7.40) was added, followed by 5 µl of 5x 
drug solutions. The plate was incubated at 37°C for 30 min. After the incubation, 25 µl of 
dye solution was added and fluorescence intensity was measured after 30 min at 37°C, using 
FlexStation II (bottom read mode, Excitation at 440 nm, Emission at 520 nm with 510 nm 
cut-off) from the Molecular Devices. Results (Relative Fluorescence Unit) were exported 
and plotted against drug concentrations in Prism 5.02 (GraphPad Software, Inc. La Jolla, 
CA) for nonlinear regression to obtain inhibitory potency. The half maximal inhibitory 
concentration were determined and expressed as pIC50 (pIC50= -log (IC50)).
Docking calculations
Docking calculations were carried out using DockingServer(9‡ as previously described to 
locate and visualize the binding site. (10) The coordinates of the crystal structure were 
obtained from the protein data bank (PDB§ with access code 4DKL for murine mu receptor 
‡http://www.dockingserver.com; last date accessed: October 15, 2013
§http://www.rcsb.org/; last date accessed: October 15, 2013
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(11) and 4DJH for kappa receptor. (12) The coordinates for the serotonin transporter were 
taken from the recently published model (13) based on the LeuT 3F3A crystal structure. (14) 
The coordinates for the norepinephrine transporter were obtained from the recently 
published model (15) based on the crystal structure (PDB ID code 2A65(16)) of LeuT from 
Aquifex aeolicus. Dezocine docking calculation on a LeuT crystal coupled with desipramine 
(PDB ID code 2QJU(17)) was also performed to identify the potential overlap of the binding 
sites. Semi-empirical charges calculated by MOPAC2009 were added to the ligand atoms**.
(18) Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters 
were added to the receptor using AutoDock tools provided by the server. Grid maps of 
30×30×30 Å grid points with 0.375 Å spacing centered at the known ligand binding site 
were generated using the Autogrid program. (19,20) All the ligand searches were performed 
using the Solis and Wets local search method with a Lamarckian genetic algorithm. (21) 
Initial position, orientation, and torsions of the ligand molecules were set randomly. The 
three-dimensional coordinates of the tested compound were obtained from the PubChem 
database††. PyMOL (Version 1.5.0.4, Schrodinger LLC, New York, NY) was used to render 
the graphics for presentation.
Data analysis
The data are presented as mean ± SE from three repeats. The results were analyzed using 
GraphPad Prism (version 5.02 Windows version). EC50s are determined using the following 
model as defined in GraphPad: Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-
X)*HillSlope)). Top and Bottom are plateaus in the units of the Y axis. EC50 is the 
concentration of a ligand that gives a response half way between Bottom and Top. HillSlope 
describes the steepness of the family of curves.
Results
Interaction with opioid receptors
While dezocine binds to all three major subtypes of opioid receptors (table 2), it only weakly 
interacts with the delta receptor. We determined affinities for dezocine as 3.7±0.7 nM for the 
human mu receptor, 527±70 nM for the human delta receptor, and 31.9±1.9 nM for the 
human kappa receptor (Table 3). As indicated in figure 2, dezocine docks to the known 
binding site for opioid ligands in both the mu and kappa receptor. Hydrogen bonding with 
ASP 147 (149 in human mu) contributes to the strong affinity of dezocine to the mu 
receptor. TYR326 also has polar interaction with dezocine in the mu receptor as 
demonstrated in figure 1A. In the case of the kappa receptor, dezocine hydrogen bonds with 
ASP 138 as predicted by docking calculations (figure 2B).
Kappa receptor antagonism
Consistent with published data, nalbuphine behaved as a full kappa receptor agonist and 
fully activated the G protein in the presence of membranes containing kappa receptor as 
indicated in figure 3A. There was no significant G protein activation with dezocine in the 
**http://openmopac.net/MOPAC2009.html; last date accessed: October 15, 2013
††http://pubchem.ncbi.nlm.nih.gov/; last date accessed: October 15, 2013
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presence of kappa receptor, indicating that dezocine acted as an antagonist (figure 3A). To 
confirm this, the G protein was pre-activated with a full agonist (Nalbuphine or Salvinorin 
A), and then increasing amounts of dezocine were added. As indicated in figure 3B, 
dezocine inhibited the agonist effect concentration-dependently with a total blockage at high 
concentration. This finding correlated the lack of G protein activation observed in figure 3A. 
The IC50 (T=30 °C) values of inhibition were in a high nanomolar range (~ 350 nM for 
competition with nalbuphine or ~800 nM for competition with salvinorin A), suggesting that 
dezocine binds to the receptor at the same site as these full agonists. Interestingly, based on 
this G protein activation study, nor-binaltorphimine acted as an inverse kappa agonist.
Amine transporter proteins as novel targets of dezocine
As indicated in table 2, in addition to binding to the opioid receptor, dezocine also inhibits 
the NET with pKi of 6.00 ± 0.10 and the SERT with pKi of 6.96±0.08. These interactions 
were further confirmed by norepinephrine and serotonin reuptake studies. The pIC50s at 
NET were 7.57±0.23 for nisoxetine (positive control) and 5.68±0.11 for dezocine (figure 
4A). The pIC50s of SERT were 5.99 ± 0.07 for nisoxetine and 5.86 ± 0.17 for dezocine 
(figure 4B).
Binding site location in NET and SERT
Consistent with the competitive binding assay, dezocine is predicted to share the same 
binding site with nisoxetine in the norepinephrine transporter as indicated in figure 5. 
Dezocine is located in close proximity to TRP103, TYR127, GLU281, and LEU368 and 
might form hydrogen bonds with these residues. Based on the docking prediction shown in 
figure 6A, dezocine binds to the preformed ligand-binding pocket in the model of human 
serotonin transporter. This pocket has been demonstrated to be the binding site for many 
selective serotonin reuptake inhibitors including fluoxetine, citalopram, sertraline, 
fluvoxamine and tricyclic antidepressants such as amitriptyline, desipramine, and 
imipramine. Mutation of the residues lining this pocket (Y95, D98,I172, Y176, F335, F341 
and S438) changed the binding capability of these ligands significantly.(13) Dezocine shares 
the same binding site for desipramine found in the crystal structure of LeuT as indicated in 
figure 6B. Both findings indicate that dezocine may share the same site as selective 
serotonin reuptake inhibitors or tricyclic antidepressants.
Discussion
This study details the discovery of the pharmacological interactions of dezocine with the 
human NET and SERT proteins as well as the molecular characterization of these 
interactions. This study also confirms the interaction of dezocine with three opioid receptors 
with different affinities and verifies that dezocine acts as an antagonist of the kappa receptor 
rather than as an agonist. Collectively, these findings have significant implications, as they 
help elucidate the mechanisms underlying dezocine’s pharmacological effects and present 
evidence supporting the compound’s potential novel clinical applications.
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Interaction with opioid receptors
Consistent with published data, (22) dezocine exhibits strong affinity for both mu and kappa 
receptors, but relatively weak interactions with the delta receptor. The determined affinities 
for all three receptors are comparable with those published previously. (22) It is predicted 
that dezocine shares the same binding site with the known ligands in the crystal structures. 
The predicted hydrogen bonding and polar interactions of dezocine in the binding sites of 
mu and kappa receptors could be used to explain why the addition of sodium ion in the 
binding buffer can decrease the affinities significantly. (22)
Dezocine is a well-known partial mu agonist (23–25) that has been used for perioperative 
pain management because of its analgesic effects.23,25 Similar to other opioids, dezocine 
could decrease anesthetic requirement by up to 50%. (26) In a double- blinded study 
comparing the analgesic effects of dezocine and meperidine in patients for postoperative 
pain management (n=187), 10 mg of dezocine produced the same analgesic activity as 50 
mg of meperidine.(1) Due to its partial agonism on the mu opioid receptor, common side 
effects observed in opioids with full agonism are significantly reduced. (27) Most 
importantly, dezocine is not a scheduled medication classified by the World Health 
Organization and no addiction related to its use has been reported. (27) Since addiction is 
one of the most significant side effects of opioids, it is critical to understand why dezocine is 
not addictive. This compound could serve as a key molecular probe to elucidate the 
mechanism(s) of addiction by comparing the molecular targets with other known addictive 
opioid molecules.
Dezocine is structurally related to the kappa agonist pentazocine. Due to this similarity, 
dezocine was initially considered a kappa agonist with the potential to generate the 
psychotomimetic effects observed with pentazocine. However, such effects were not 
observed in analgesic dosages for dezocine used in clinical trials. (1) In fact, a recent study 
suggested that dezocine is a kappa antagonist.(3) We confirmed this finding by 
demonstrating the compound’s inability to activate the receptor and its capacity to 
antagonize the agonist effects of salvinorin A, a potent and highly selective kappa receptor 
agonist, and nalbuphine, a non-selective kappa receptor agonist. Further study is needed to 
demonstrate whether this kappa receptor antagonism is connected to the compound’s lack of 
addictive properties. (28) Buprenorphine, a partial mu agonist and kappa antagonist, has 
been successfully used for addiction treatment for many years with the outcome equivalent 
to methadone therapy. (29) However, buprenorphine itself is an addictive Schedule III 
medication (30) and its chronic use creates significant difficulty for optimal perioperative 
pain management due to its high affinity to the receptor and long half-life. (31–33) Similar 
to buprenorphine, dezocine is also a partial mu agonist and a kappa antagonist based on our 
current findings. Further study is warranted to demonstrate whether dezocine, a non-
addictive compound, could be used as a potential alternative medication for addiction 
management. Its shorter half-life allows for easier titration to an optimal effect as well as 
rapid removal when full agonism is required during the perioperative period.
While nor-binaltorphimine was traditionally considered a kappa antagonist, this study’s 
finding is consistent with the report that nor-binaltorphimine is an inverse kappa agonist, a 
property which may be related to its antidepressive effects.(34)
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Interaction with NET and its related clinical implications
While dezocine is a mu opioid receptor partial antagonist, theoretically, it could antagonize 
the anti-nociceptive effects of morphine. However, when used in combination with 
morphine, dezocine concentration-dependently enhances the analgesic effects of morphine. 
(35) The combination of morphine and dezocine also reduces the anesthetic requirement. 
(26) These suggest the existence of alternative targets for dezocine (beside the opioid 
receptors) that could have additive effects for other opioids. Our findings support these 
earlier pharmacological observations. Dezocine interacts with NET and inhibits the 
norepinephrine reuptake. The competitive binding assay and the computational docking 
calculation suggest that dezocine interacts with NET directly at the binding site for the 
intrinsic NET ligand. Interestingly, a recent study indicates that pentazocine, a compound 
structurally similar to dezocine, inhibits NET function by reducing the amount of NET in 
cell surface membranes through an opioid receptor-independent pathway. (36) It is unclear 
whether dezocine could have similar properties as pentazocine in regards to indirect NET 
interaction. NET plays an important role in pain pathways and norepinephrine reuptake 
inhibition could be used for treating pain, (37) especially in neuropathic pain. (38) While its 
direct interaction with NET is relatively weak, it is still worthwhile to investigate whether 
dezocine could be used to target neuropathic pain in addition to its opioid receptor mediated 
analgesia.
Interaction with SERT and its related clinical implications
One of the striking findings of this study is that dezocine interacts with SERT at its ligand 
binding site and that serotonin reuptake can be inhibited concentration-dependently by 
dezocine. It is important to note that since dezocine shares a binding site with some clinical 
antidepressant drugs such as fluoxetine, sertraline, and amitriptyline, cross interactions may 
occur. Thus precaution may be needed. The kappa opioid receptor, NET and SERT are all 
important targets for depression treatment.(39–42) Because dezocine interacts with all three 
targets, it is critical to investigate whether or not dezocine could be an alternative medication 
to treat depression and prevent opioid-induced depression. Opioids are the main class of 
medications used to manage moderate and severe pain; however, in addition to addiction, 
depression is another common side effect of chronic opioid usage. (43) Patients with chronic 
pain frequently report depression, a condition associated with high pain intensity and greater 
prevalence of chronic opioid therapy. (44) Identifying and treating depression symptoms in 
chronic pain patients are essential for reducing co-morbidity and disability. (45) 80% of 
patients with major depression without psychotic features have painful physical symptoms. 
(46) Consequently, there is a significant medical impetus for developing medications that 
simultaneously and effectively target pain and depression. In vivo studies are warranted to 
demonstrate whether dezocine is a medication of choice targeting both pain and depression 
due to its unique molecular targets of kappa receptor antagonism, NET and SERT inhibition. 
Potential drug interaction could occur when using similar drugs with shared binding site(s).
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The major limitation of this study is that the profiling was limited to 44 receptors available 
to us and it is possible that dezocine could interact with additional targets. No in vivo 
evidence is provided in this study.
In conclusion, this study explored the interaction of dezocine with three major opioid 
receptors, demonstrated that dezocine is a kappa antagonist, and suggested its potential use 
for addition treatment. Through molecular target profiling, we discovered two novel 
molecular targets of dezocine in vitro: NET and SERT. The binding sites were characterized 
using available structural models and docking experiments. Dezocine concentration-
dependently inhibited norepinephrine and serotonin reuptake in vitro. These findings suggest 
the potential use of dezocine as a novel medication for the simultaneous treatment of pain 
and depression. Potential drug interactions should be considered when administering drugs 
with similar pharmacological targets. Further studies are warranted.
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The structures of the ligands used in this study to probe the pharmacological properties of 
dezocine are listed. All structures were obtained from public domain without further 
modification or verification by a chemist except salvinorin A and JDTic. Salvinorin A 
(http://commons.wikimedia.org/wiki/File:Salvinorin-A_structure.png) and JDTic (http://
commons.wikimedia.org/wiki/File:JDTic_cas_361444-66-8.svg) are obtained from 
Wikimedia Commons and are licensed under the Creative Commons Attribution-Share 
Alike 3.0 Unported license.
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A) Dezocine (magenta) overlaps with beta-Funaltrexamine (orange,) a mu receptor 
antagonist and the ligand found in the crystal structure of the mu opioid receptor (4DKL13, 
in the binding pocket. Polar interaction with ASP147 and TYR326 is predicted. B) Dezocine 
(magenta) overlaps with JDTic (orange), a kappa receptor antagonist and the ligand found in 
the crystal structure of the kappa opioid receptor (4DJH) 14, in the binding pocket. Some of 
interacting residues (ASP 138, TYR 139 and MET 142) are colored in yellow. A nitrogen in 
dezocine might hydrogen bond with oxygen atoms of ASP 138 (distance colored in 
magenta, 2.6 Å, or in green, 2.8 Å).
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A) Nalbuphine and salvinorin A, full agonists of kappa opioid receptors, concentration 
dependently activate the G protein in the presence of kappa receptor. Dezocine fails to 
induce any G protein activation, indicating receptor antagonism. Based on the activity of the 
G protein in its presence, nor-binaltorphimine is an inverse agonist of kappa opioid receptor. 
B) G protein was pre-activated with a full agonist (Nalbuphine, 250 nM or Salvinorin A, 20 
nM) and then increasing amounts of dezocine was added. Dezocine inhibited the agonist 
effects of nalbuphine and salvinorin A concentration-dependently with a total blockage at 
high concentration, confirming the kappa receptor antagonism effect of dezocine. The 
relationship is plotted using the following model: Y=Bottom + (Top-Bottom)/
(1+10^((LogEC50-X)*HillSlope)).
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A) Norepinephrine reuptake is dose dependently inhibited by both dezocine and nisoxetine. 
However, inhibition is weaker in the case of dezocine. B) Serotonin reuptake is 
concentration dependently inhibited in the presence of dezocine and nisoxetine with 
comparable potency. The relationship is plotted using the following model: Y=Bottom + 
(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)).
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Docking result of dezocine and nisoxetine in the model of norepinephrine transporter (NET). 
Dezocine (magenta) shares the same binding site of nisoxetine (cyan), a NET inhibitor, as 
indicated by the close overlap. Dezocine is located in close proximity to TRP103, TYR127, 
GLU281, and LEU368 which are all colored in yellow.
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A) Dezocine (magenta) sits in the preformed ligand binding pocket for selective serotonin 
reuptake inhibitors in the model of human serotonin transporter. The key interacting residues 
lining the pocket (Y95, D98, I172, Y176, F335, F341, and S438) are colored in yellow. This 
binding pocket has been demonstrated to be the binding site for many important clinical 
drugs such as fluoxetine, sertraline, and amitriptyline. B) Dezocine (magenta) shares the 
same binding pocket and overlap well with desiprimine (orange), the ligand in the LeuT 
crystal structure (2QJU).
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